Psoriatic Arthritis

Fatigue numeric rating scale validity, discrimination and responder definition in patients with psoriatic arthritis
Dafna Gladman, Peter Nash, Hitoshi Goto, Julie A Birt, Chen-Yen Lin, Ana-Maria Orbai, Tore K Kvien

RMD Open Jan 2020, 6 (1) e000928; DOI: 10.1136/rmdopen-2019-000928
Transition phase towards psoriatic arthritis: clinical and ultrasonographic characterisation of psoriatic arthralgia
Alen Zabotti, Dennis G McGonagle, Ivan Giovannini, Enzo Errichetti, Francesca Zuliani, Anna Zanetti, Ilaria Tinazzi, Orazio De Lucia, Alberto Batticciotto, Luca Idolazzi, Garifallia Sakellariou, Sara Zandonella Callegher, Stefania Sacco, Luca Quartuccio, Annamaria Iagnocco, Salvatore De Vita

RMD Open Oct 2019, 5 (2) e001067; DOI: 10.1136/rmdopen-2019-001067
Measurement properties of the minimal disease activity criteria for psoriatic arthritis
Laura C Coates, Vibeke Strand, Hilary Wilson, Dennis Revicki, Brad Stolshek, Ahmed Samad, James B Chung, Dafna Gladman, Philip J Mease

RMD Open Sep 2019, 5 (2) e001002; DOI: 10.1136/rmdopen-2019-001002
Secukinumab does not impair the immunogenic response to the influenza vaccine in patients
Patricia Richi, María Dolores Martín, Fernando de Ory, Rosa Gutiérrez-Larraya, Inmaculada Casas, Ana María Jiménez-Díaz, Fernando Cava, Santiago Muñoz-Fernandez

RMD Open Sep 2019, 5 (2) e001018; DOI: 10.1136/rmdopen-2019-001018
Efficacy of ustekinumab in biologic-naïve patients with psoriatic arthritis by prior treatment exposure and disease duration: data from PSUMMIT 1 and PSUMMIT 2
Iain B McInnes, Soumya D Chakravarty, Isabel Apaolaza, Shelly Kafka, Elizabeth C Hsia, Yin You, Arthur Kavanaugh

RMD Open Aug 2019, 5 (2) e000990; DOI: 10.1136/rmdopen-2019-000990
Does a mandatory non-medical switch from originator to biosimilar etanercept lead to increase in healthcare use and costs? A Danish register-based study of patients with inflammatory arthritis
Bente Glintborg, Rikke Ibsen, Rebecca Elisabeth Qwist Bilbo, Merete Lund Hetland, Jakob Kjellberg

RMD Open Aug 2019, 5 (2) e001016; DOI: 10.1136/rmdopen-2019-001016
Patients with psoriatic arthritis who are not eligible for randomised controlled trials for TNF inhibitors have treatment response and drug survival similar to those who are eligible
Olafur Palsson, Thorvardur Jon Love, Anna Ingibjorg Gunnarsdottir, Petur Sigurdur Gunnarsson, Eydis Erla Runarsdottir, Niels Steen Krogh, Bjorn Gudbjornsson

RMD Open Jul 2019, 5 (2) e000984; DOI: 10.1136/rmdopen-2019-000984
Long-term safety of certolizumab pegol in rheumatoid arthritis, axial spondyloarthritis, psoriatic arthritis, psoriasis and Crohn’s disease: a pooled analysis of 11 317 patients across clinical trials
Jeffrey R Curtis, Xavier Mariette, Cécile Gaujoux-Viala, Andrew Blauvelt, Tore K Kvien, William J Sandborn, Kevin Winthrop, Marc de Longueville, Ivo Huybrechts, Vivian P Bykerk

RMD Open May 2019, 5 (1) e000942; DOI: 10.1136/rmdopen-2019-000942
Body mass index and treatment response to subcutaneous abatacept in patients with psoriatic arthritis: a post hoc analysis of a phase III trial
Iain B McInnes, Gianfranco Ferraccioli, Maria-Antonietta D'Agostino, Manuela Le Bars, Subhashis Banerjee, Harris A Ahmad, Yedid Elbez, Philip J Mease

RMD Open May 2019, 5 (1) e000934; DOI: 10.1136/rmdopen-2019-000934
Understanding the association between skin involvement and joint activity in patients with psoriatic arthritis: experience from the Corrona Registry
Philip J Mease, Carol J Etzel, William J Huster, Talia M Muram, April W Armstrong, Jeffrey R Lisse, Sabrina Rebello, Rhiannon Dodge, Mwangi James Murage, Jeffrey D Greenberg, William N Malatestinic

RMD Open May 2019, 5 (1) e000867; DOI: 10.1136/rmdopen-2018-000867

Main menu

Psoriatic Arthritis

Pages

Log in using your username and password

Main menu

Log in using your username and password

You are here

Psoriatic Arthritis

Pages